Completed PHASE3 INTERVENTIONAL 7-arm NCT01087762

Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis

Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis

Sponsor: UCB BIOSCIENCES GmbH

Conditions Spondyloarthropathies

Interventions CZP 200 mg Q2W CZP 400 mg Q4W Placebo

Updated 8 times since 2017 Last updated: Jul 4, 2018 Started: Mar 31, 2010 Primary completion: Oct 31, 2011 Completion: Aug 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Spondyloarthropathies, this trial is completed. The trial is conducted by UCB BIOSCIENCES GmbH and has accumulated 8 data snapshots since 2010. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Aug 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 3 earlier versions

Jun 2018 — Aug 2018 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Mar 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

UCB BIOSCIENCES GmbH

Data source: UCB Pharma

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ancona, Italy , Asheville, United States , Aventura, United States , Barnsley, United Kingdom , Berlin, Germany , Bialystok, Poland , Birmingham, United States , Boulogne-Billan Court, France , Brno, Czechia , Brooklyn, United States and 86 more locations